Biogen Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

$BIIB stock is up 3% today. Here's what we see in our data. - Quiver Quantitative

📈 $BIIB stock gained 3% today with trading volume reaching approximately $29.5 million.

🔍 The ticker ranked as the 38th most-searched on Quiver Quantitative out of over 11,000 tickers.

💼 Insiders traded shares three times in the last six months, resulting in two sales and one purchase.

🏢 Institutional investor activity showed a split with 456 adding shares while 453 reduced positions recently.

💰 Biogen reported Q4 2025 revenue of $2.3 billion, marking a 7.14% decline year-over-year.

👥 Members of Congress executed one trade in the past six months involving only a purchase.

📊 Wall Street analysts issued three buy ratings against one sell rating on the stock recently.

🎯 A median price target of $200 was set by 19 analysts over the last six months for $BIIB.

⚠️ Investors should note that this data comes from Quiver Quantitative and is not financial advice.

Bullish Signals
  • $BIIB stock is up 3% today, indicating positive market momentum according to Polygon price data.
  • 456 institutional investors added shares of $BIIB to their portfolios in the most recent quarter, demonstrating increased institutional confidence.
  • Wall Street analysts have issued positive sentiment with 3 firms issuing buy ratings on the stock against only 1 firm issuing sell ratings.
  • Multiple analysts support higher valuations, with 19 analysts offering price targets for $BIIB in the last 6 months including a median target of $200.0.
  • Members of Congress have shown bullish activity by purchasing $BIIB stock once in the past 6 months with no sales recorded during that period.
Risk Factors
  • $BIIB insiders sold the stock twice in the past 6 months compared to only one purchase, signaling potential lack of confidence among company leadership.
  • Institutional investors decreased their positions in the most recent quarter, with 453 reducing shares while only 456 added them.
  • Revenues dropped -7.14% year-over-year in Q4 2025 to $2.3B, indicating declining top-line performance.
  • One Wall Street firm issued a sell rating on the stock despite three firms issuing buy ratings, highlighting mixed analyst sentiment.
Full Analysis
Shares of $BIIB rose 3% today according to price data from Polygon, with approximately $29.5 million in trading volume recorded over the period. The stock ranked as the 38th most-searched ticker among 11,337 total tickers tracked on Quiver Quantitative over the past day. This daily performance reflects ongoing market interest in the biotechnology company, which saw specific activity from both insiders and institutional investors. Insider trading data indicates that $BIIB stock has been traded by corporate insiders three times in the last six months, consisting of one purchase and two sales. Institutional investor positions have shifted, with 456 investors adding shares to their portfolios while 453 decreased their holdings during the most recent quarter. Congressional members also participated in the market, with one purchase recorded over the past six months and no sales made by these officials. Analyst sentiment remains mixed but positive regarding future price expectations. In the last several months, three firms issued buy ratings on the stock while one firm released a sell rating. Of 19 analysts who provided price targets for $BIIB in the last six months, the median target stands at $200.0. Financially, the company reported revenues of $2.3 billion for Q4 2025, which represents a decline of 7.14% compared to the same period in the prior year. Readers interested in tracking these developments live can monitor Quiver Quantitative's dedicated stock page for real-time data on trading volume, insider transactions, and institutional holdings. The platform also offers dashboards specifically for analyzing hedge fund portfolios, congressional stock trading history, and detailed forecast pages showing analyst price targets and ratings. As with all financial reporting, the article notes potential inaccuracies may occur due to ticker-mapping errors or other anomalies and advises that this content is not financial advice.